PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30186451-0 2018 Andrographolide attenuates viral myocarditis through interactions with the IL-10/STAT3 and P13K/AKT/NF-kappabeta signaling pathways. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 96-99 33597499-10 2019 Andrographolide administration also decreased the levels of phosphorylated NF-kappaB p65 (Ser536) and phosphorylated Akt (Ser473) in liver of malaria- infected animals. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 117-120 30186451-7 2018 Results indicated that andrographolide treatment reduced serum levels of TNF-alpha, hs-CRP and cTnl, increased the expression levels of IL-10 and STAT3 and reduced the expression levels of NF-kappabeta p65 and NF-kappabeta p50 and the phosphorylation levels of phosphoinositide 3-kinase (P13K) and AKT in the heart tissues of mice with VMC. andrographolide 23-38 thymoma viral proto-oncogene 1 Mus musculus 298-301 21512969-6 2011 In BV-2 cells, OGD induced ROS and nitric oxide production by upregulating NOX2 and iNOS via the phosphatidylinositol-3-kinase (PI3K)/AKT-dependent NF- kappaB and HIF-1 alpha pathways, and these changes were suppressed by andrographolide and LY294002. andrographolide 222-237 thymoma viral proto-oncogene 1 Mus musculus 134-137 27378149-0 2016 Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-kappaB pathway. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 131-134 27378149-13 2016 Additionally, andrographolide inhibited Akt/NF-kappaB signaling pathway. andrographolide 14-29 thymoma viral proto-oncogene 1 Mus musculus 40-43 27183596-11 2016 Andrographolide significantly restored nuclear HDAC2 protein levels and total HDAC activity, and it diminished the total histone acetyltransferase/HDAC activity ratio in mouse lungs exposed to LPS/IFN-gamma, possibly via suppression of PI3K/Akt/HDAC2 phosphorylation, and upregulation of the antioxidant transcription factor NF erythroid-2-related factor 2 level and DNA binding activity. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 241-244 25869056-0 2015 Andrographolide suppresses melanin synthesis through Akt/GSK3beta/beta-catenin signal pathway. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 53-56 25869056-10 2015 6-Bromoindirubin-3"-oxime (BIO, inhibitor of GSK3beta) and insulin-like growth factors-1 (IGF-1, activator of Akt) could reverse the decline of beta-catenin in B16F10 cells induced by andrographolide. andrographolide 184-199 thymoma viral proto-oncogene 1 Mus musculus 110-113 25869056-11 2015 CONCLUSION: These results demonstrate that andrographolide can effectively suppress melanin content and TYR activity in B16F10 cells, HEM cells and UVB-induced brown guinea pig skin by decreasing phosphorylation of GSK3beta dependent on Akt, promoting the degradation of beta-catenin, inhibiting beta-catenin into the nucleus and decreasing the expression of MITF and TYR family. andrographolide 43-58 thymoma viral proto-oncogene 1 Mus musculus 237-240 21512969-0 2011 Andrographolide inhibits PI3K/AKT-dependent NOX2 and iNOS expression protecting mice against hypoxia/ischemia-induced oxidative brain injury. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 30-33 21822619-6 2011 Andrographolide inhibited collagen-stimulated platelet activation accompanied by relative Ca(2+) mobilization; thromboxane A(2) formation; and phospholipase C (PLC)gamma2, protein kinase C (PKC), mitogen-activated protein kinase (MAPK), and Akt phosphorylation. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 241-244 21822619-9 2011 ODQ, an inhibitor of guanylate cyclase, markedly reversed the andrographolide-mediated inhibitory effects on platelet aggregation, p38 MAPK and Akt phosphorylation, and the andrographolide-mediated stimulatory effect on VASP phosphorylation. andrographolide 62-77 thymoma viral proto-oncogene 1 Mus musculus 144-147 21822619-13 2011 This study demonstrates for the first time that andrographolide possesses a novel role of antiplatelet activity, which may involve the activation of the eNOS-NO/cyclic GMP pathway, resulting in the inhibition of the PI3 kinase/Akt-p38 MAPK and PLCgamma2-PKC cascades, thereby leading to inhibition of platelet aggregation. andrographolide 48-63 thymoma viral proto-oncogene 1 Mus musculus 227-230 21512969-7 2011 Our results indicate that andrographolide reduces NOX2 and iNOS expression possibly by impairing PI3K/AKT-dependent NF- kappaB and HIF-1 alpha activation. andrographolide 26-41 thymoma viral proto-oncogene 1 Mus musculus 102-105 35048242-0 2022 Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF-kappaB and PI3K/AKT Signaling In Vitro and In Vivo. andrographolide 0-15 thymoma viral proto-oncogene 1 Mus musculus 125-128 20139902-8 2010 Reduced phosphorylation levels of ERK1/2 and AKT were observed in macrophages treated with andrographolide. andrographolide 91-106 thymoma viral proto-oncogene 1 Mus musculus 45-48 35048242-5 2022 In in vivo study, the antitumor effect of Andro (10 mg/kg) was evaluated by 5637 tumor-bearing mice, and levels of nuclear factor kappaB (NF-kappaB) and phosphoinositide 3-kinase/AKT related-proteins were determined by immunoblotting. andrographolide 42-47 thymoma viral proto-oncogene 1 Mus musculus 179-182 35048242-10 2022 CONCLUSIONS: Andrographolide inhibits proliferation and promotes apoptosis in bladder cancer cells by interfering with NF-kappaB and PI3K/AKT signaling in vitro and in vivo. andrographolide 13-28 thymoma viral proto-oncogene 1 Mus musculus 138-141